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We have recently identiﬁed a new clinical syndrome in patients receiving warfarin for
anticoagulation therapy. This syndrome has been named warfarin-related nephro-
pathy (WRN), and patients with chronic kidney disease (CKD) appear to be
particularly susceptible. WRN is deﬁned as an acute increase in international
normalized ratio (INR) to 43.0, followed by evidence of acute kidney injury (AKI)
within 1 week of the INR increase. AKI was deﬁned as a sustained increase in serum
creatinine of greater than or equal to 0.3 mg/dL. The AKI cannot be explained by any
other factors, and the kidney biopsy demonstrates extensive glomerular hemorrhage
with tubular obstruction by red blood cells (RBCs). Beyond AKI, WRN is a signiﬁcant
risk factor for mortality within the ﬁrst 2 months of diagnosis and it accelerates the
progression of CKD. We demonstrated that 5/6 nephrectomy in rats is a suitable
experimental model to study WRN. Animals treated with warfarin showed an
increase in serum creatinine and morphologic ﬁndings in the kidney similar to those
in humans with WRN. Our recent evidence suggests that novel oral anticoagulants
may induce AKI. Diagnosis of WRN may be challenging for a renal pathologist. A few
cases with suspected WRN and pathologic considerations are described.
& 2014. The Korean Society of Nephrology. Published by Elsevier. This is an open
access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Anticoagulant therapy is vital for patients with thromboem-
bolic disorders, most notably atrial ﬁbrillation or deep vein
thrombosis. An estimated 4 million patients in the US and
almost 7 million worldwide are receiving long-term therapy
with oral anticoagulants, primarily warfarin or other coumarin
derivatives, for prevention and treatment of venous and arterial
thromboembolism [1]. Vitamin K antagonists, such as warfarin
(Coumadin), provide reliable protection against thromboembolic
events. However, this beneﬁt comes at a cost, which is a risk of
hemorrhage resulting from coagulopathy. Recently, evidencen Society of Nephrology. Publi
c-nd/4.0/).
hology, The Ohio State
all, B078, Columbus, OHthat warfarin-related coagulopathy may lead to kidney compli-
cations, including acute kidney injury (AKI), was reported [2–4].
This complication was reported in the USA [2–4] and Korea [5].
Worrisome data that even novel oral anticoagulants may also
affect the kidney were recently reported [6,7].
This review focuses on the discovery of anticoagulant-
related kidney injury, describes an animal model to study it,
and provides guidance for nephrologists and renal patholo-
gists who may encounter this disease.Clinical aspects of anticoagulation and AKI
Chronic kidney disease (CKD) is one of the major health
problems in the world [8], where between 10% and 15% of the
population are diagnosed with this condition [9,10]. Anticoagula-
tion therapy is commonly required in CKD patients for treatmentshed by Elsevier. This is an open access article under the CC BY-NC-ND
Brodsky / Anticoagulants and acute kidney injury 175or prevention of thromboembolic disorders. It has been shown
that CKD patients are at high risk of developing atrial ﬁbrillation,
which requires anticoagulation therapy, and as many as 21% of
nondialysis CKD patients may have atrial ﬁbrillation, as compared
with 1.5–6.2% in the general population [11]. Among the patients
diagnosed with atrial ﬁbrillation, more than a third have CKD
Stage 3 and above [12]. Warfarin is the most prescribed antic-
oagulant in the world and more than 2 million people start
warfarin therapy every year in the USA alone. Warfarin treatment
requires constant monitoring of the international normalized ratio
(INR) and dose adjustments should be made to keep the INR
within the therapeutic range. Monitoring of INR is difﬁcult, costly,
and there is a level of noncompliance. CKD is associated with
decreased anticoagulation stability in patients onwarfarin therapy,
which, in turn, requires more frequent and intensive clinical
management [13]. Avoiding over-anticoagulation in CKD appears
to be a frequent problem. Limdi et al [14] compared complications
of warfarin therapy among 578 patients with different stages of
CKD. They reported that patients with severe CKD were at higher
risk for both over-anticoagulation and major hemorrhage, as
compared with patients with mild or moderate CKD. Chan et al
[15] reported that warfarin therapy is associated with higher
mortality among hemodialysis patients than in non–end-stage
renal disease (ESRD) CKD patients. Their study included 41,425
hemodialysis patients; 8.3% were receiving warfarin therapy.
Warfarin therapy was associated with a 27% increase in mortality.
Several adverse effects of warfarin overdose on kidney
function have been described, including hemorrhages, vascu-
litis, interstitial nephritis, and hematuria [16,17]. Our group
described AKI associated with warfarin treatment [2–4]. We
named this condition warfarin-related nephropathy (WRN).
It has been suggested that warfarin can cause AKI by
inducing glomerular hematuria with subsequent widespread
tubular obstruction. This was ﬁrst reported in a patient with
severe warfarin coagulopathy and thin glomerular basement
membrane (GBM) disease [18]. Later, evidence of a similar
syndrome in a patient with inactive systemic lupus erythema-
tosus (SLE), with an abnormally thick GBM, was reported [19].
The mechanism of the AKI in these patients likely involved the
unusual combination of very severe warfarin coagulopathy (INR in
the 6–9 range) in which the patient had either abnormally thin
GBM [18] or abnormally thick GBM [19], both of which are risk
factors for spontaneous gross hematuria [20]. Thus, based on these
cases, there was no compelling reason to believe that AKI would
be a common complication of warfarin therapy. This notion,
however, was dispelled by our kidney biopsy study of nine
instances of WRN in seven patients who developed unexplained
AKI during only moderate over-anticoagulation with warfarin
(mean INR 4.470.7) [4]. The kidney biopsies showed widespread
and severe tubular obstruction by red blood cell (RBC) casts.
Although these patients had CKD, their glomeruli were normal or
showed only minor changes. Thus, the renal biopsy evidence of
severe glomerular hematuria was unexpected. Also, most of the
WRN patients showed little or no recovery of kidney function [4].
The next work by our group was a retrospective analysis of
103 consecutive warfarin-treated CKD patients followed in our
Nephrology program from January 2005 until June 2009. Of
these, 49 experienced at least one episode of INR 43.0. Of
these, 18 (37%) developed an unexplained increase in serum
creatinine Z 0.3 mg/dL within 1 week of the INR 43.0, and
their CKD progression was accelerated [2].
Another evidence of the broad clinical signiﬁcance of WRN
is an analysis of 4,006 warfarin-treated patients [3]. Eachexperienced an INR 43.0 and serum creatinine was measured
within 1 week of the increased INR. The analysis of this large
database (4,006 patients) [3] supports the analysis of the
smaller database (103 patients) [2] that showed that WRN is
common in CKD patients (37% develop AKI at ﬁrst onset of INR
43.0). The new insight of this study is that WRN is also
common in no-CKD patients and is signiﬁcantly associated
with an increased risk of mortality.
Based on these publications, the key clinical features of WRN
are: (1) evidence of AKI appears shortly after the INR acutely
increases to43.0; (2) kidney biopsies in these patients show acute
tubular injury associated with severe and widespread occlusive
RBC casts; (3) WRN accelerates the progression of CKD; (4) WRN
occurs in approximately 37% (CKD) to 16% (no-CKD) of warfarin-
treated patients whose INR acutely rises to43.0; (5) patients with
WRN have a signiﬁcantly increased mortality rate.
We observed that WRN may occur in some patients who do
not have the clinical diagnosis of CKD. Our experimental data
show that control animals treated with warfarin do not
develop AKI even if their prothrombin time (PT) increases
more than ﬁve times [21,22]. This raises the possibility that the
people who develop WRN without apparent CKD probably had
some underlying kidney injury.
Several other groups have described WRN in patients on
warfarin therapy [5,23]. Their data conﬁrmed our observa-
tions, including a high incidence of WRN. The main conclu-
sions from published data are: The risk of AKI occurs at an INR threshold of 43; AKI
risk is not a function of the level of INR beyond 3. The kidney biopsy ﬁndings in those with AKI and INR
43 are consistent with catastrophic glomerular hemor-
rhage causing tubular injury. An abnormally elevated INR is not sufﬁcient by itself to
cause WRN; we postulate that WRN occurs in the setting
of pre-existing glomerular damage (which may not have
been clinically known/diagnosed) coupled with over-
anticoagulation. Normal patients who develop WRN likely
have undiagnosed CKD/glomerular injury. When speciﬁcally analyzed, WRN is associated with
progression of CKD and an increased risk of subacute
mortality. The true incidence of WRN is difﬁcult to determine from
the mainly retrospective studies published thus far, but
it appears to be high. The only prospective study [23]
suggests an incidence of 60%, at least in the elderly
population examined.
Adding to this public health problem is emerging evidence
that WRN is only a subset of a broader syndrome, that probably
is anticoagulant-related nephropathy (ARN) in which other, and
possibly all, currently used anticoagulants may cause AKI.
Indeed, AKI associated with dabigatran (direct thrombin inhi-
bitor) use has been reported in humans [6,24,25] and was
recently demonstrated by our group in experimental animals
[7]. In addition, anticoagulants may aggravate an underlying
kidney disease and induce hematuria and AKI [26].
Experimental models of WRN
First, our group demonstrated that excessive anticoagula-
tion by superwarfarin (brodifacoum) reproduces morphologic
Kidney Res Clin Pract 33 (2014) 174–180176features of WRN in 5/6 nephrectomized rats [22]. These rats
had increased serum creatinine levels, glomerular hemor-
rhage, occlusive RBC casts, and acute tubular injury in the
kidney, which closely resembled the ﬁndings in kidney biop-
sies from patients with WRN [4]. By contrast, treatment with
brodifacoum did not affect renal function in control animals. It
appears that kidney injury develops shortly after the INR
increase [22]. Later, our group demonstrated that the 5/6
nephrectomy in rats is a suitable model to study WRN.
Warfarin resulted in a dose-dependent increase in serum
creatinine in 5/6 nephrectomy rats [21]. The increase in serum
creatinine associated with warfarin treatment was greater in
animals at 3 weeks and 19 weeks after the ablative surgery.
The serum creatinine increase was correlated with the PT
increase. Kidney morphology in 5/6 nephrectomy rats showed
acute tubular injury with RBCs and RBC casts in the tubules.
Treatment with vitamin K prevented serum creatinine increase
and morphologic changes in the kidney associated with
warfarin treatment [21].
The next step in understanding of the pathogenesis of WRN
was to investigate the role of oxidative stress. Our group
demonstrated that treatment with the antioxidant N-acetyl-
cysteine (NAC) does not prevent glomerular hemorrhage but
does prevent AKI in 5/6 nephrectomy rats [27]. We found that
NAC in a dose-dependent manner prevents serum creatinine
increase associated with excessive anticoagulation by warfarin.
However, NAC could not prevent either hematuria or RBC cast
formation in 5/6 nephrectomy rats, suggesting that oxidative
stress plays a little, if any, role in the glomerular ﬁltration
barrier injury and glomerular hemorrhage associated with
warfarin treatment. Nevertheless, NAC in a dose-dependent
manner prevented serum creatinine increase in 5/6 nephrect-
omy rats treated with warfarin, suggesting that acute tubular
injury seen in WRN is diminished. Indeed, morphologically
animals treated with NAC had lesser acute tubular injury as
compared with warfarin-only treated 5/6 nephrectomy rats
[27]. Therefore, we believe that oxidative stress plays an
important role in the deterioration of renal function and acute
tubular necrosis in WRN. Our data suggests the following
mechanisms of increased oxidative stress in the kidney in
WRN: (1) free hemoglobin released by RBCs in the tubular
lumen affects tubular epithelial cells by generating reactive
oxygen species and increased lipid peroxidation [28]; (2) free
hemoglobin incorporates into the tubular epithelial cells via
several surface receptors, such as megalin-cubilin receptors
[29]; intracellularly, free hemoglobin activates caspases and
induces apoptosis [30]; (3) intracellular hemoglobin dissoci-
ates into globin and heme, while the latter is also a potent
oxidant and activates proinﬂammatory pathways [29,31]. It is
unlikely that free iron plays a signiﬁcant role in the pathogen-
esis of acute tubular injury, because staining for iron is
negative in tubular epithelial cells and treatment with the
iron chelator deferoxamine (DFO) does not affect WRN in 5/6
nephrectomy rats. Our ﬁndings indicated that glomerular
hematuria is a necessary but not sufﬁcient mechanism for
the AKI in WRN. The dominant mechanism of WRN is probably
tubular obstruction by RBC casts, which leads to increased
oxidative stress in the kidney [27].
We recently reported worrisome evidences that novel oral
anticoagulants, such as the direct thrombin inhibitor dabigatran,
may also induce AKI in experimental animals [7]. We demon-
strated that dabigatran increases serum creatinine in a dose-
dependent manner in 5/6 nephrectomy rats, similar to theeffects of warfarin in this experimental model, as we reported
earlier [21]. Unexpectedly, similar elevation in serum creatinine
was seen in control, nonoperated rats treated with dabigatran.
The 5/6 nephrectomy rats were more sensitive to dabigatran and
developed hematuria earlier and after lower doses of dabigatran
as compared with control rats. Morphologically, the ﬁndings in
5/6 nephrectomy rats treated with dabigatran were similar to
those found in animals with WRN [21,22].
Our ﬁndings, that dabigatran affects kidney function, change
our view on the pathogenesis of WRN. After the ﬁrst publica-
tions of our works based on vitamin K antagonists [4,21,22],
there was no compelling evidence that other anticoagulants
might affect the kidney. Taking our ﬁndings with vitamin K
antagonists and dabigatran together, we currently hypothesize
that the pathogenesis of WRN does not include vitamin K-
dependent proteins. The common result of both vitamin K
antagonists and direct thrombin inhibitors is diminished
thrombin activity. By acting on thrombomodulin, which is
expressed on endothelial cells, thrombin activates protein C
and modulates the anticoagulation cascade. Another important
receptor for thrombin, which is also expressed on endothelial
cells, is proteinase activated receptor 1 (PAR-1). PAR-1 is a G
protein-coupled receptor and it participates in the regulation of
endothelial functions, vascular permeability, leukocyte migra-
tion, and adhesion [32,33]. In vitro studies indicate that PAR-1
activation changes endothelial monolayer integrity [34]. We
propose that thrombin plays an important role in the glomer-
ular ﬁltration barrier function, and its decreased activity (sec-
ondary to anticoagulation) results in glomerular ﬁltration
barrier abnormalities. Indeed, our data indicate that treatment
with selective PAR-1 inhibitor SCH79797 results in increased
serum creatinine, hematuria, and tubular RBC casts. Interest-
ingly, these ﬁndings were more pronounced in 5/6 nephrect-
omy than in control rats, indicating that ablative nephropathy
by itself makes kidneys more sensitive to changes in coagulation
disturbances and it is probably related to changes in PAR-1. In
fact, decreased PAR-1 protein expression was found in several
human kidney diseases, such as crescentic glomerulonephritis
and thrombotic microangiopathy [35,36]. Of note, despite the
fact that changes in coagulation parameters were similar to
those that are recommended for patients [37,38], dabigatran
affected renal function and induced hematuria in concentrations
signiﬁcantly higher than those used for humans [38]. These
differences may be explained by different pharmacodynamics
and pharmacokinetics of dabigatran in rats, which require a
signiﬁcantly higher dose of this drug than humans to achieve
the same degree of anticoagulation [39,40]. This raises the
possibility of direct nephrotoxic effects of dabigatran [7].
Our latest data indicate that anticoagulants increase blood
pressure (BP) in rats [41]. Warfarin and dabigatran both
increased systolic BP in control and 5/6 nephrectomy rats in a
dose-dependent manner. SCH79797 also increased systolic BP in
a dose-dependent manner. Vitamin K prevented the warfarin-
induced increase in BP. NAC delayed the warfarin-associated
increase in BP. Interestingly, the warfarin effects on BP were
similar in 5/6 nephrectomy rats at different CKD stages. A few
early reports suggest that warfarin treatment may be associated
with hypertension in animals [42] and humans [43]. Liu et al
described a warfarin-associated increase in systolic BP in rats, but
this study focused mainly on arterial calciﬁcation induced by
long-term treatment with warfarin, which was presumed to
cause the increase in BP [42]. Similar conclusions were reported
by Dao et al [44] and Essalihi et al [45], who also performed
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Brodsky / Anticoagulants and acute kidney injury 177chronic treatment with warfarin and vitamin K. Krishnan et al
[43] analyzed the Stroke Prevention in Non-Rheumatic Atrial
Fibrillation (SPINAF) trial, which included 525 subjects, and they
found a signiﬁcant elevation in the pulse pressure of warfarin-
treated patients with hypertension. However, no signiﬁcant
changes in BP were seen by these [42,43] or other authors
[46] in patients receiving long-term warfarin treatment (2–3
years). This discrepancy between our data and previously
published data may be explained by the duration of the
treatment (acute vs. chronic) and by possible adjustment of
antihypertensive drugs for better BP control in the patients.
Based on our data, the hypertensive effect of warfarin does
not change with CKD progression. Indeed, the BP increase from
baseline was similar in sham-operated rats and in 5/6
nephrectomy rats at different stages of CKD progression [41].
These data suggest that CKD patients may not be at a higher
risk for hypertension associated with warfarin.Ta
b
le
1.
D
em
o
gr
ap
h
ic
s,
la
b
o
ra
to
ry
d
at
a,
an
d
m
o
rp
h
o
lo
gi
c
ﬁ
n
d
in
gs
in
p
at
ie
n
ts
w
it
h
w
ar
fa
ri
n
-r
el
at
ed
n
ep
h
ro
p
at
h
y
(W
R
N
)n
Pa
ti
en
t
A
ge
G
en
d
er
R
ac
e
M
ax
im
al
IN
R
(I
U
)
SC
r
ch
an
ge
fr
om
B
L
(m
g/
d
L)
U
ri
n
al
ys
is
A
TN
R
B
C
ca
st
s
(%
)
Im
m
u
n
oﬂ
u
or
es
ce
n
ce
G
B
1
27
F
A
A
8.
0
2.
5
3
þ
h
em
at
u
ri
a,
1
þ
p
ro
te
in
u
ri
a
1
þ
2.
8
1
þ
m
es
an
gi
al
Ig
G
,
Ig
M
,C
1q
,C
3
2
76
F
W
7.
0
2.
5
2
þ
h
em
at
u
ri
a
3
þ
20
.9
N
on
sp
ec
iﬁ
c
3
61
M
W
2.
0
1.
8
2
þ
h
em
at
u
ri
a,
3
þ
p
ro
te
in
u
ri
a
2
þ
4.
4
N
on
sp
ec
iﬁ
c
4
80
M
W
5.
2
2.
6
2
þ
h
em
at
u
ri
a,
2
þ
p
ro
te
in
u
ri
a
3
þ
16
.8
1
þ
m
es
an
gi
al
Ig
A
5
38
F
W
3.
9
1.
3
1
þ
h
em
at
u
ri
a,
1
þ
p
ro
te
in
u
ri
a
1
þ
2.
3
1
þ
m
es
an
gi
al
Ig
A
6
63
M
W
3.
7
1.
5
2
þ
h
em
at
u
ri
a,
R
B
C
ca
st
s
1
þ
16
.3
N
on
sp
ec
iﬁ
c
7
82
F
W
2.
8
3.
4
1
þ
h
em
at
u
ri
a
2
þ
to
3
þ
17
.8
1
þ
m
es
an
gi
al
Ig
A
8
73
M
W
3.
0
3.
9
2
þ
h
em
at
u
ri
a,
3
þ
p
ro
te
in
u
ri
a
3
þ
10
.9
N
on
sp
ec
iﬁ
c
9
55
M
W
3.
8
8.
3
1
þ
h
em
at
u
ri
a,
1
þ
p
ro
te
in
u
ri
a
3
þ
11
.4
1
þ
m
es
an
gi
al
Ig
G
,
C
1q
,C
3
n
M
or
p
h
ol
og
ic
al
ﬁ
n
d
in
gs
w
er
e
sc
or
ed
se
m
iq
u
an
ti
ta
ti
ve
ly
u
si
n
g
th
e
fo
llo
w
in
g
cr
it
er
ia
:
0,
ab
se
n
t;
1
þ
,m
ild
;
2
þ
,m
od
er
at
e;
3
þ
,p
ro
m
in
en
t.
If
ch
w
as
ap
p
lie
d
.
†
Th
e
m
ea
n
G
B
M
th
ic
kn
es
s
es
ta
bl
is
h
ed
in
ou
r
la
bo
ra
to
ry
fo
r
m
al
es
w
as
37
3
7
56
n
m
an
d
fo
r
fe
m
al
es
w
as
35
1
7
40
n
m
.
A
A
,A
fr
ic
an
A
m
er
ic
an
;
A
TN
,a
cu
te
tu
bu
la
r
n
ec
ro
si
s;
B
L,
ba
se
lin
e;
C
,c
om
p
le
m
en
t;
G
B
M
,g
lo
m
er
u
la
r
ba
se
m
en
t
m
em
br
an
e;
Ig
,i
m
m
u
n
og
lo
bu
lin
u
n
it
s;
R
B
C
,r
ed
bl
oo
d
ce
ll;
SC
r,
se
ru
m
cr
ea
ti
n
in
e;
W
,w
h
it
e.Considerations for a renal pathologist to suspect WRN
in a kidney biopsy
There is a challenge for a renal pathologist to recognize
WRN in kidney biopsy. Renal pathologists often do not
recognize WRN because of an underlying kidney disease.
Acute tubular injury and RBC casts are usually associated
with those conditions. In our ﬁrst description of WRN, a
variety of underlying kidney disease was found (Table 1) [4].
No guidelines have been established yet to diagnose WRN.
Here are two recent examples of WRN diagnosis from our
practice.
Case 1. A 61-year-old Caucasian female with recently
diagnosed diabetes mellitus. Her baseline serum creatinine
was normal. She presented to hospital following episodes of
diarrhea with serum creatinine of 3.2 mg/dL. She developed
deep vein thrombosis and she was started on warfarin
therapy. Her INR was as high as 5. Her serum creatinine
increased up to 6.6 mg/dL within 2 weeks after initiation of
warfarin therapy. Serologies showed positive antinuclear
antibody (ANA; 1:640), but her complement levels were
normal. Kidney biopsy ﬁndings by light microscopy
included numerous RBC casts and acute tubular necrosis
(Fig. 1A). The glomeruli were unremarkable (Fig. 1B). Immu-
noﬂuorescence showed mild smudgy staining for immuno-
globulin G (IgG) (Fig. 1C). Electron microscopy showed
scattered small electron dense immune-type complex
deposits (Fig. 1D). There was a disproportion between the
number of RBC casts, the degree of acute tubular necrosis,
and relatively small immune complex deposits in the
absence of proliferative glomerular lesions or cellular
crescents.
Case 2. A 41-year-old Caucasian female with history of
aortic bifurcation thrombosis. She underwent a graft
placement and started on warfarin therapy. Her INR was
as high as 27. Her baseline serum creatinine was 1.0 mg/
dL, but this increased to 6.7 mg/dL shortly after the high
INR. Urinalysis showed hematuria with RBC casts. Her
serologies [ANA; antineutrophil cytoplasmic antibodies
(ANCA)] were negative and her complement levels were
normal. In a kidney biopsy, immunoﬂuorescence did not
Figure 1. Light microscopy, immunoﬂuorescence, and electron microscopy in a patient with suspicious warfarin-related nephropathy (WRN)
(Case 1). (A) Light microscopy shows numerous red blood cell (RBC) casts in the tubules and acute tubular necrosis. Hematoxylin and Eosin,
magniﬁcation 40 . (B) Glomeruli are unremarkable by light microscopy. Periodic acid–Schiff stain, magniﬁcation 200 . (C) Direct immunoﬂuor-
escence with an antibody to IgG shows mild mesangial staining. Magniﬁcation 200 . (D) Electron microscopy shows scattered mesangial electron-
dense immune-type deposits (arrow). Magniﬁcation 10,000 .
Figur 2. Light microscopy in a patient with suspicious warfarin-
related nephropathy (WRN) (Case 2). Light microscopy shows numer-
ous red blood cell (RBC) casts in the tubules and acute tubular necrosis.
Hematoxylin and Eosin, magniﬁcation 200 .
Kidney Res Clin Pract 33 (2014) 174–180178show positive staining. Electron microscopy showed nor-
mal GBM thickness. However, by light microscopy there
were numerous tubular RBC casts and acute tubular
necrosis (Fig. 2).
It is not clear whether other anticoagulants, including new
oral drugs, can induce AKI. A case of dabigatran-induced AKI
has been reported [6]. Our own observations include a kidney
biopsy from a patient on heparin therapy, where we have seen
numerous RBC casts and acute tubular necrosis as well. We
believe that anticoagulant-related kidney injury should be
suspected in a patient on anticoagulation therapy, if there is
a disproportion between the number of RBC tubular casts,
acute tubular necrosis, and the degree of an underlying kidneylesion (such as glomerular immune complex depositions, GBM
thickness abnormalities, etc.) in kidney biopsy. Detailed eva-
luation of coagulation data and medications is recommended
for all patients with RBC casts and AKI.Conﬂict of interest
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